Therapeutics and Clinical Risk Management (Jul 2022)
Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
Abstract
Aisha Shaikh,1 Justina Ray,2 Kirk N Campbell2 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence: Kirk N Campbell, Department of Medicine, Box 1243, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA, Tel +1212-241-6271, Fax +1212-987-0389, Email [email protected]: Diabetes is the leading cause of chronic and end stage kidney disease globally. Despite recent advances in therapies for diabetic kidney disease (DKD), there remains a critical need for additional options to improve renal and cardiovascular outcomes. Mineralocorticoid overactivation contributes to inflammation and fibrosis which in turn leads to progression of DKD. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has shown promising cardiac and renoprotective benefits in DKD. The utility of finerenone in the real world will require appropriate patient selection and patient monitoring by clinicians.Keywords: finerenone, diabetes, chronic kidney disease
